➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Medtronic
Harvard Business School
AstraZeneca
McKesson

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,722,473


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,722,473 protect, and when does it expire?

Patent 10,722,473 protects ADHANSIA XR and is included in one NDA.

Summary for Patent: 10,722,473
Title:Methods and compositions particularly for treatment of attention deficit disorder
Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
Inventor(s): Donnelly; Graeme (Toronto, CA), Bhaskar; Sailaja (Pickering, CA)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:16/195,418
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 10,722,473

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-001 Feb 27, 2019 RX Yes No   Get Started Free   Get Started Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)   Get Started Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-002 Feb 27, 2019 RX Yes No   Get Started Free   Get Started Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)   Get Started Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-003 Feb 27, 2019 RX Yes No   Get Started Free   Get Started Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)   Get Started Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-004 Feb 27, 2019 RX Yes No   Get Started Free   Get Started Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)   Get Started Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-005 Feb 27, 2019 RX Yes No   Get Started Free   Get Started Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)   Get Started Free
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-006 Feb 27, 2019 RX Yes Yes   Get Started Free   Get Started Free METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Merck
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.